Literature DB >> 21308921

Self-adjuvanting multicomponent cancer vaccine candidates combining per-glycosylated MUC1 glycopeptides and the Toll-like receptor 2 agonist Pam3CysSer.

Brendan L Wilkinson1, Stephanie Day, Lara R Malins, Vasso Apostolopoulos, Richard J Payne.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21308921     DOI： 10.1002/anie.201006115

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN： 1433-7851            Impact factor:   15.336


× No keyword cloud information.
  40 in total

1.  Protective Epitope Discovery and Design of MUC1-based Vaccine for Effective Tumor Protections in Immunotolerant Mice.

Authors:  Xuanjun Wu; Zhaojun Yin; Craig McKay; Christian Pett; Jin Yu; Manuel Schorlemer; Trevor Gohl; Suttipun Sungsuwan; Sherif Ramadan; Claire Baniel; Anthony Allmon; Rupali Das; Ulrika Westerlind; M G Finn; Xuefei Huang
Journal:  J Am Chem Soc       Date:  2018-11-19       Impact factor: 15.419

2.  Combining synthetic carbohydrate vaccines with cancer cell glycoengineering for effective cancer immunotherapy.

Authors:  Lei Qiu; Xi Gong; Qianli Wang; Jie Li; Honggang Hu; Qiuye Wu; Junping Zhang; Zhongwu Guo
Journal:  Cancer Immunol Immunother       Date:  2012-04-27       Impact factor: 6.968

3.  Carbohydrate-monophosphoryl lipid a conjugates are fully synthetic self-adjuvanting cancer vaccines eliciting robust immune responses in the mouse.

Authors:  Qianli Wang; Zhifang Zhou; Shouchu Tang; Zhongwu Guo
Journal:  ACS Chem Biol       Date:  2011-11-01       Impact factor: 5.100

4.  Recent progress in antitumoral synthetic vaccines.

Authors:  Cristina Nativi; Olivier Renaudet
Journal:  ACS Med Chem Lett       Date:  2014-09-29       Impact factor: 4.345

5.  Design of a MUC1-based tricomponent vaccine adjuvanted with FSL-1 for cancer immunotherapy.

Authors:  Mingjing Li; Zhaoyu Wang; Bocheng Yan; Xiaona Yin; Yue Zhao; Fan Yu; Meng Meng; Yonghui Liu; Wei Zhao
Journal:  Medchemcomm       Date:  2019-07-12       Impact factor: 3.597

Review 6.  Tumor-associated O-glycans of MUC1: Carriers of the glyco-code and targets for cancer vaccine design.

Authors:  Donella M Beckwith; Maré Cudic
Journal:  Semin Immunol       Date:  2020-01-09       Impact factor: 11.130

7.  Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide.

Authors:  Nitin T Supekar; Vani Lakshminarayanan; Chantelle J Capicciotti; Anju Sirohiwal; Cathy S Madsen; Margreet A Wolfert; Peter A Cohen; Sandra J Gendler; Geert-Jan Boons
Journal:  Chembiochem       Date:  2017-11-30       Impact factor: 3.164

8.  Synthesis of glycoimmunogen Tn-Thr-PS A1 via hydrazone bond and stability optimization of PS A1 monosaccharide mimics under vaccine development conditions.

Authors:  F Hossain; S Nishat; S Ghosh; S Boga; G T Hymel; P R Andreana
Journal:  J Carbohydr Chem       Date:  2020-02-03       Impact factor: 1.667

9.  Synthesis of a Liposomal MUC1 Glycopeptide-Based Immunotherapeutic and Evaluation of the Effect of l-Rhamnose Targeting on Cellular Immune Responses.

Authors:  Partha Karmakar; Kyunghee Lee; Sourav Sarkar; Katherine A Wall; Steven J Sucheck
Journal:  Bioconjug Chem       Date:  2015-12-09       Impact factor: 4.774

10.  Design, Synthesis, and Preliminary Immunological Studies of MUC1-Based Antitumor Vaccines Adjuvanted with R- and S-FSL-1.

Authors:  Yonghui Liu; Bocheng Yan; Zhaoyu Wang; Haomiao Zhu; Xiaona Yin; Kun Wang; Menglei Wang; Wei Zhao
Journal:  ACS Med Chem Lett       Date:  2020-06-22       Impact factor: 4.345
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.